Catheter Securement Devices Market by Product Type (Adhesive Securement Devices, Integrated Securement And Dressing Products, Subcutaneous Anchoring Devices), Catheter Type (Arterial Catheter, Central Venous Catheter, Dialysis Catheter), Application, End
Description
The Catheter Securement Devices Market was valued at USD 1.21 billion in 2024 and is projected to grow to USD 1.27 billion in 2025, with a CAGR of 6.43%, reaching USD 2.00 billion by 2032.
A clear orientation to device classes, clinical priorities, and procurement drivers that define contemporary catheter securement strategies and hospital decision-making
Catheter securement devices have emerged as a critical intersection between clinical safety, device engineering, and procurement policy. This introduction situates the landscape by outlining the principal device categories, clinical use cases, and the evolving expectations of healthcare providers and payers. Over recent years, care teams have demanded solutions that reduce complication rates, streamline bedside workflows, and integrate with dressing and monitoring systems, driving innovation across adhesive, integrated dressing, subcutaneous anchoring, and suture-based approaches.
Clinical teams increasingly prioritize securement technologies that balance fixation strength with skin integrity, particularly for patients with fragile skin or prolonged catheter dwell times. As a result, product developers are focusing on materials science, low-trauma adhesives, and modular systems that support both acute and chronic care pathways. Concurrently, procurement professionals are seeking evidence of value through peer-reviewed outcomes, real-world performance metrics, and total cost of care implications.
Taken together, these dynamics create a market environment where device performance must be demonstrated across diverse catheter types and settings. This report begins by mapping those intersections, clarifying how clinical pressure points translate into design priorities, regulatory scrutiny, and pathway-specific adoption barriers that stakeholders will need to navigate.
How integrated device design, minimally invasive anchoring, data-driven procurement, and decentralized care models are redefining catheter securement practice
The catheter securement landscape is undergoing transformative shifts driven by clinical demands, technological advances, and shifting care delivery models. First, there is a pronounced move toward integrated solutions that combine adhesive securement with dressing functions to simplify clinical procedures and reduce manipulation events. Manufacturers are responding with platforms that offer modularity and compatibility across catheter types, enabling smoother transitions between acute and outpatient care.
Second, the adoption of less invasive anchoring mechanisms has accelerated, with subcutaneous and low-profile anchoring systems gaining attention for their potential to mitigate infection risk and patient discomfort. Innovation is being informed by multidisciplinary collaboration between clinicians, materials scientists, and device engineers, resulting in products that aim to reduce skin trauma while maintaining reliable fixation.
Third, digital health and data-driven procurement are reshaping how adoption decisions are made. Hospitals and specialty clinics increasingly expect evidence from integration studies, electronic medical record workflows, and performance dashboards that demonstrate reductions in line-related complications. Lastly, as care shifts toward outpatient infusion, home-based therapies, and ambulatory surgical centers, device form factors and supply chain models are adapting to support decentralized care without sacrificing safety or clinician usability.
How the 2025 United States tariff adjustments reshaped sourcing strategies, compliance obligations, and supplier resilience across securement device supply chains
The cumulative impact of tariff changes in the United States during 2025 has introduced new considerations across sourcing, pricing, and supply chain resilience for securement device stakeholders. Supply managers and manufacturers were prompted to reassess supplier footprints and nearshoring opportunities to mitigate exposure to import duties, which in turn influenced sourcing strategies for raw materials, subassemblies, and finished devices.
As procurement pathways adjusted, distributors and hospital systems reviewed contract terms to preserve budget predictability and to prioritize suppliers with diversified manufacturing bases. In parallel, regulatory and customs compliance teams faced increased scrutiny of product classifications and country-of-origin documentation, raising administrative burdens for vendors and purchasers.
These dynamics accelerated conversations about supplier consolidation, strategic inventory positioning, and collaborative contracting models that share risk between providers and suppliers. Importantly, the tariff environment also catalyzed innovation in cost containment through design simplification and material substitution where clinically acceptable. Going forward, organizations that proactively manage tariff-driven complexity through supplier due diligence, flexible contract structures, and targeted product portfolio adjustments will be better positioned to sustain clinical supply continuity and pricing stability.
Detailed segmentation insights that link product types, catheter categories, clinical applications, and end-user dynamics to targeted adoption strategies and evidence needs
Understanding segmentation is essential to align product development, clinical validation, and go-to-market strategies. Product type distinctions-adhesive securement devices, integrated securement and dressing products, subcutaneous anchoring devices, and suture securement devices-reflect different engineering trade-offs between ease of use, fixation strength, and skin preservation, and each pathway demands unique clinical evidence and training programs.
Catheter type variation further refines clinical positioning: arterial catheters, central venous catheters, dialysis catheters, and peripheral intravenous catheters present discrete risk profiles, dwell-time expectations, and handling practices. Manufacturers must therefore tailor materials, attachment mechanisms, and instructions for use to the hemodynamic and infection-prevention priorities inherent to each catheter class.
Application-focused segmentation into acute catheter, chronic catheter, and hemodialysis catheter contexts shapes requirements for longevity, patient comfort, and dressing-change protocols. Meanwhile, end user segmentation across ambulatory surgical centers, home healthcare, hospitals, and specialty clinics dictates distribution models and educational needs, with hospitals further differentiated by private and public status, which influences procurement cycles and reimbursement frameworks.
When these segmentation layers are considered together, they reveal where clinical value propositions should be targeted, which clinical trials or real-world evidence programs will most effectively demonstrate benefit, and how commercialization strategies must be adapted by channel and care setting.
Regional strategic considerations for market entry and adoption that reconcile global product platforms with distinct regulatory, procurement, and clinical practice realities
Regional dynamics significantly affect adoption patterns, reimbursement frameworks, and regulatory pathways. In the Americas, evolving hospital procurement practices and growing emphasis on infection prevention have driven uptake of integrated securement and dressing systems, while decentralized care trends have increased demand for devices suited to ambulatory and home infusion environments.
Across Europe, Middle East & Africa, diverse regulatory regimes and hospital funding models generate heterogeneity in device adoption, with private hospital networks often adopting innovations more quickly than public systems. The region’s emphasis on harmonized clinical guidelines and cross-border standardization also places a premium on evidence packages that meet multiple national requirements simultaneously.
In the Asia-Pacific region, rapid expansion of hospital infrastructure, rising chronic disease burdens, and growing home healthcare penetration have created opportunities for manufacturers with scalable production capabilities and localized regulatory strategies. Regional variation in clinician preferences and supply chain logistics requires tailored market entry plans and partnerships to navigate reimbursement pathways and to accelerate clinician training in newer securement techniques.
Overall, regional strategy must reconcile global product platforms with local regulatory, procurement, and clinical practice realities to achieve sustainable adoption across diverse healthcare ecosystems.
How competition is shaped by clinical partnerships, evidence generation, scalable manufacturing, and differentiated service models that influence procurement decisions
Competitive patterns reveal a mix of specialized securement innovators and larger device manufacturers integrating securement capabilities into broader portfolio offerings. Leading suppliers differentiate through clinical partnerships, evidence generation, and investments in low-trauma materials and modular design. These firms prioritize robust clinician training and post-market surveillance to demonstrate real-world performance and to support hospital procurement committees.
Smaller, specialized companies often compete by rapidly iterating on design, focusing on niche catheter types or clinical applications, and offering flexible trial programs to health systems. Conversely, larger manufacturers leverage scale, established distribution networks, and cross-sell opportunities within vascular access and infusion portfolios to accelerate adoption across hospital networks and ambulatory settings.
Across the competitive landscape, strategic collaboration between manufacturers, academic centers, and healthcare systems has become a recurring pattern. These collaborations produce comparative effectiveness data and implementation playbooks that materially influence purchasing decisions. For suppliers considering market expansion, the imperative is clear: combine demonstrable clinical outcomes with predictable supply continuity and a service model that addresses training, inventory, and economic evaluation needs.
Concrete and prioritized recommendations for manufacturers, suppliers, and provider procurement teams to accelerate safe adoption and strengthen market resilience
Industry leaders should adopt a series of practical actions to strengthen market position and to accelerate safe adoption. First, prioritize clinical evidence programs that target key catheter types and applications where securement interventions can deliver measurable reductions in complications and workflow burden. Designing studies that align with hospital quality metrics and payer interests will facilitate smoother adoption and procurement approval.
Second, invest in supply chain diversification and near-term inventory strategies to mitigate tariff and trade disruption risks while maintaining cost competitiveness. Developing transparent contract terms and collaborative stocking arrangements with large health systems can reduce budgetary friction and support predictable supply continuity.
Third, create integrated commercial and clinical education programs that address insertion technique, dressing maintenance, and device troubleshooting. Embedding training within existing vascular access curricula and leveraging digital learning tools will reduce variation in practice and accelerate clinician confidence.
Lastly, pursue selective partnerships with healthcare providers and pilot sites to generate real-world evidence and to iterate product design based on user feedback. By aligning product development with validated clinical outcomes and by demonstrating a clear service model, industry leaders can lower barriers to adoption and improve long-term commercial performance.
A transparent and robust mixed-methods research approach combining clinician interviews, secondary literature synthesis, and multi-stakeholder validation to ensure practical reliability
The research methodology combined multi-source data collection, stakeholder interviews, and iterative validation to ensure analytical rigor. Primary research involved structured interviews with clinicians, procurement leaders, and supplier executives to capture first-hand perspectives on device performance, clinical workflows, and purchasing drivers, while secondary research synthesized peer-reviewed literature, regulatory guidance, and manufacturing trend reports to contextualize primary insights.
Data triangulation was employed to reconcile differing perspectives and to identify consistent themes across clinical settings and regions. The methodological approach emphasized transparency in source attribution and bias mitigation, with interview samples stratified by specialty, care setting, and geographic region to ensure representativeness. Qualitative insights from pilot programs and hospital implementation notes were cross-referenced with published infection-control guidelines and device labeling to confirm clinical plausibility.
Where quantitative inputs were used to inform scenario analysis, they were drawn from validated public sources and vetted through expert panels to avoid overreliance on any single dataset. The result is a methodological framework that supports actionable conclusions while acknowledging the inherent variability in clinical practice and procurement environments.
Concluding synthesis emphasizing evidence-led adoption, supply chain resilience, and integrated commercial strategies to secure sustainable market success
In conclusion, catheter securement devices occupy a pivotal role in advancing patient safety, reducing line-related complications, and enabling the broader shift toward decentralized care. The convergence of integrated device design, minimally invasive anchoring, and data-driven procurement is creating multiple pathways for adoption, yet success will hinge on demonstrable clinical outcomes, resilient supply chains, and tailored regional strategies.
Stakeholders that align product development with specific catheter types and application settings, while investing in evidence generation and clinician training, will be best positioned to capture clinical and commercial value. Moreover, navigating trade dynamics and regulatory heterogeneity requires proactive supply chain planning and close collaboration with healthcare partners to ensure uninterrupted access and predictable budgeting.
Ultimately, informed, evidence-led decision-making coupled with flexible commercialization and service models will determine which organizations achieve sustainable adoption. This conclusion underscores the importance of integrating clinical, regulatory, and commercial perspectives into a cohesive strategy for the securement device category.
Please Note: PDF & Excel + Online Access - 1 Year
A clear orientation to device classes, clinical priorities, and procurement drivers that define contemporary catheter securement strategies and hospital decision-making
Catheter securement devices have emerged as a critical intersection between clinical safety, device engineering, and procurement policy. This introduction situates the landscape by outlining the principal device categories, clinical use cases, and the evolving expectations of healthcare providers and payers. Over recent years, care teams have demanded solutions that reduce complication rates, streamline bedside workflows, and integrate with dressing and monitoring systems, driving innovation across adhesive, integrated dressing, subcutaneous anchoring, and suture-based approaches.
Clinical teams increasingly prioritize securement technologies that balance fixation strength with skin integrity, particularly for patients with fragile skin or prolonged catheter dwell times. As a result, product developers are focusing on materials science, low-trauma adhesives, and modular systems that support both acute and chronic care pathways. Concurrently, procurement professionals are seeking evidence of value through peer-reviewed outcomes, real-world performance metrics, and total cost of care implications.
Taken together, these dynamics create a market environment where device performance must be demonstrated across diverse catheter types and settings. This report begins by mapping those intersections, clarifying how clinical pressure points translate into design priorities, regulatory scrutiny, and pathway-specific adoption barriers that stakeholders will need to navigate.
How integrated device design, minimally invasive anchoring, data-driven procurement, and decentralized care models are redefining catheter securement practice
The catheter securement landscape is undergoing transformative shifts driven by clinical demands, technological advances, and shifting care delivery models. First, there is a pronounced move toward integrated solutions that combine adhesive securement with dressing functions to simplify clinical procedures and reduce manipulation events. Manufacturers are responding with platforms that offer modularity and compatibility across catheter types, enabling smoother transitions between acute and outpatient care.
Second, the adoption of less invasive anchoring mechanisms has accelerated, with subcutaneous and low-profile anchoring systems gaining attention for their potential to mitigate infection risk and patient discomfort. Innovation is being informed by multidisciplinary collaboration between clinicians, materials scientists, and device engineers, resulting in products that aim to reduce skin trauma while maintaining reliable fixation.
Third, digital health and data-driven procurement are reshaping how adoption decisions are made. Hospitals and specialty clinics increasingly expect evidence from integration studies, electronic medical record workflows, and performance dashboards that demonstrate reductions in line-related complications. Lastly, as care shifts toward outpatient infusion, home-based therapies, and ambulatory surgical centers, device form factors and supply chain models are adapting to support decentralized care without sacrificing safety or clinician usability.
How the 2025 United States tariff adjustments reshaped sourcing strategies, compliance obligations, and supplier resilience across securement device supply chains
The cumulative impact of tariff changes in the United States during 2025 has introduced new considerations across sourcing, pricing, and supply chain resilience for securement device stakeholders. Supply managers and manufacturers were prompted to reassess supplier footprints and nearshoring opportunities to mitigate exposure to import duties, which in turn influenced sourcing strategies for raw materials, subassemblies, and finished devices.
As procurement pathways adjusted, distributors and hospital systems reviewed contract terms to preserve budget predictability and to prioritize suppliers with diversified manufacturing bases. In parallel, regulatory and customs compliance teams faced increased scrutiny of product classifications and country-of-origin documentation, raising administrative burdens for vendors and purchasers.
These dynamics accelerated conversations about supplier consolidation, strategic inventory positioning, and collaborative contracting models that share risk between providers and suppliers. Importantly, the tariff environment also catalyzed innovation in cost containment through design simplification and material substitution where clinically acceptable. Going forward, organizations that proactively manage tariff-driven complexity through supplier due diligence, flexible contract structures, and targeted product portfolio adjustments will be better positioned to sustain clinical supply continuity and pricing stability.
Detailed segmentation insights that link product types, catheter categories, clinical applications, and end-user dynamics to targeted adoption strategies and evidence needs
Understanding segmentation is essential to align product development, clinical validation, and go-to-market strategies. Product type distinctions-adhesive securement devices, integrated securement and dressing products, subcutaneous anchoring devices, and suture securement devices-reflect different engineering trade-offs between ease of use, fixation strength, and skin preservation, and each pathway demands unique clinical evidence and training programs.
Catheter type variation further refines clinical positioning: arterial catheters, central venous catheters, dialysis catheters, and peripheral intravenous catheters present discrete risk profiles, dwell-time expectations, and handling practices. Manufacturers must therefore tailor materials, attachment mechanisms, and instructions for use to the hemodynamic and infection-prevention priorities inherent to each catheter class.
Application-focused segmentation into acute catheter, chronic catheter, and hemodialysis catheter contexts shapes requirements for longevity, patient comfort, and dressing-change protocols. Meanwhile, end user segmentation across ambulatory surgical centers, home healthcare, hospitals, and specialty clinics dictates distribution models and educational needs, with hospitals further differentiated by private and public status, which influences procurement cycles and reimbursement frameworks.
When these segmentation layers are considered together, they reveal where clinical value propositions should be targeted, which clinical trials or real-world evidence programs will most effectively demonstrate benefit, and how commercialization strategies must be adapted by channel and care setting.
Regional strategic considerations for market entry and adoption that reconcile global product platforms with distinct regulatory, procurement, and clinical practice realities
Regional dynamics significantly affect adoption patterns, reimbursement frameworks, and regulatory pathways. In the Americas, evolving hospital procurement practices and growing emphasis on infection prevention have driven uptake of integrated securement and dressing systems, while decentralized care trends have increased demand for devices suited to ambulatory and home infusion environments.
Across Europe, Middle East & Africa, diverse regulatory regimes and hospital funding models generate heterogeneity in device adoption, with private hospital networks often adopting innovations more quickly than public systems. The region’s emphasis on harmonized clinical guidelines and cross-border standardization also places a premium on evidence packages that meet multiple national requirements simultaneously.
In the Asia-Pacific region, rapid expansion of hospital infrastructure, rising chronic disease burdens, and growing home healthcare penetration have created opportunities for manufacturers with scalable production capabilities and localized regulatory strategies. Regional variation in clinician preferences and supply chain logistics requires tailored market entry plans and partnerships to navigate reimbursement pathways and to accelerate clinician training in newer securement techniques.
Overall, regional strategy must reconcile global product platforms with local regulatory, procurement, and clinical practice realities to achieve sustainable adoption across diverse healthcare ecosystems.
How competition is shaped by clinical partnerships, evidence generation, scalable manufacturing, and differentiated service models that influence procurement decisions
Competitive patterns reveal a mix of specialized securement innovators and larger device manufacturers integrating securement capabilities into broader portfolio offerings. Leading suppliers differentiate through clinical partnerships, evidence generation, and investments in low-trauma materials and modular design. These firms prioritize robust clinician training and post-market surveillance to demonstrate real-world performance and to support hospital procurement committees.
Smaller, specialized companies often compete by rapidly iterating on design, focusing on niche catheter types or clinical applications, and offering flexible trial programs to health systems. Conversely, larger manufacturers leverage scale, established distribution networks, and cross-sell opportunities within vascular access and infusion portfolios to accelerate adoption across hospital networks and ambulatory settings.
Across the competitive landscape, strategic collaboration between manufacturers, academic centers, and healthcare systems has become a recurring pattern. These collaborations produce comparative effectiveness data and implementation playbooks that materially influence purchasing decisions. For suppliers considering market expansion, the imperative is clear: combine demonstrable clinical outcomes with predictable supply continuity and a service model that addresses training, inventory, and economic evaluation needs.
Concrete and prioritized recommendations for manufacturers, suppliers, and provider procurement teams to accelerate safe adoption and strengthen market resilience
Industry leaders should adopt a series of practical actions to strengthen market position and to accelerate safe adoption. First, prioritize clinical evidence programs that target key catheter types and applications where securement interventions can deliver measurable reductions in complications and workflow burden. Designing studies that align with hospital quality metrics and payer interests will facilitate smoother adoption and procurement approval.
Second, invest in supply chain diversification and near-term inventory strategies to mitigate tariff and trade disruption risks while maintaining cost competitiveness. Developing transparent contract terms and collaborative stocking arrangements with large health systems can reduce budgetary friction and support predictable supply continuity.
Third, create integrated commercial and clinical education programs that address insertion technique, dressing maintenance, and device troubleshooting. Embedding training within existing vascular access curricula and leveraging digital learning tools will reduce variation in practice and accelerate clinician confidence.
Lastly, pursue selective partnerships with healthcare providers and pilot sites to generate real-world evidence and to iterate product design based on user feedback. By aligning product development with validated clinical outcomes and by demonstrating a clear service model, industry leaders can lower barriers to adoption and improve long-term commercial performance.
A transparent and robust mixed-methods research approach combining clinician interviews, secondary literature synthesis, and multi-stakeholder validation to ensure practical reliability
The research methodology combined multi-source data collection, stakeholder interviews, and iterative validation to ensure analytical rigor. Primary research involved structured interviews with clinicians, procurement leaders, and supplier executives to capture first-hand perspectives on device performance, clinical workflows, and purchasing drivers, while secondary research synthesized peer-reviewed literature, regulatory guidance, and manufacturing trend reports to contextualize primary insights.
Data triangulation was employed to reconcile differing perspectives and to identify consistent themes across clinical settings and regions. The methodological approach emphasized transparency in source attribution and bias mitigation, with interview samples stratified by specialty, care setting, and geographic region to ensure representativeness. Qualitative insights from pilot programs and hospital implementation notes were cross-referenced with published infection-control guidelines and device labeling to confirm clinical plausibility.
Where quantitative inputs were used to inform scenario analysis, they were drawn from validated public sources and vetted through expert panels to avoid overreliance on any single dataset. The result is a methodological framework that supports actionable conclusions while acknowledging the inherent variability in clinical practice and procurement environments.
Concluding synthesis emphasizing evidence-led adoption, supply chain resilience, and integrated commercial strategies to secure sustainable market success
In conclusion, catheter securement devices occupy a pivotal role in advancing patient safety, reducing line-related complications, and enabling the broader shift toward decentralized care. The convergence of integrated device design, minimally invasive anchoring, and data-driven procurement is creating multiple pathways for adoption, yet success will hinge on demonstrable clinical outcomes, resilient supply chains, and tailored regional strategies.
Stakeholders that align product development with specific catheter types and application settings, while investing in evidence generation and clinician training, will be best positioned to capture clinical and commercial value. Moreover, navigating trade dynamics and regulatory heterogeneity requires proactive supply chain planning and close collaboration with healthcare partners to ensure uninterrupted access and predictable budgeting.
Ultimately, informed, evidence-led decision-making coupled with flexible commercialization and service models will determine which organizations achieve sustainable adoption. This conclusion underscores the importance of integrating clinical, regulatory, and commercial perspectives into a cohesive strategy for the securement device category.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of antimicrobial and hydrocolloid securement devices to reduce catheter related infections
- 5.2. Emergence of sutureless and skin adhesive securement technologies improving patient comfort and mobility
- 5.3. Integration of smart sensor technology for continuous monitoring of catheter stabilization integrity
- 5.4. Rising preference for transparent breathable dressings promoting skin health under securement
- 5.5. Increasing regulatory approvals and reimbursement support for innovative catheter stabilization solutions
- 5.6. Growth of single use disposable securement systems to minimize cross contamination in clinical environments
- 5.7. Focus on pediatric and geriatric specific catheter securement designs addressing demographic clinical needs
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Catheter Securement Devices Market, by Product Type
- 8.1. Adhesive Securement Devices
- 8.2. Integrated Securement And Dressing Products
- 8.3. Subcutaneous Anchoring Devices
- 8.4. Suture Securement Devices
- 9. Catheter Securement Devices Market, by Catheter Type
- 9.1. Arterial Catheter
- 9.2. Central Venous Catheter
- 9.3. Dialysis Catheter
- 9.4. Peripheral Intravenous Catheter
- 10. Catheter Securement Devices Market, by Application
- 10.1. Acute Catheter
- 10.2. Chronic Catheter
- 10.3. Hemodialysis Catheter
- 11. Catheter Securement Devices Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Home Healthcare
- 11.3. Hospitals
- 11.3.1. Private Hospitals
- 11.3.2. Public Hospitals
- 11.4. Specialty Clinics
- 12. Catheter Securement Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Catheter Securement Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Catheter Securement Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. 3M Company
- 15.3.2. Avanos Medical, Inc.
- 15.3.3. Baxter International Inc.
- 15.3.4. Becton, Dickinson and Company
- 15.3.5. BioDerm, Inc.
- 15.3.6. Centurion Medical Products Corporation
- 15.3.7. Dale Medical Products, Inc.
- 15.3.8. DeRoyal Industries, Inc.
- 15.3.9. ICU Medical, Inc.
- 15.3.10. Medtronic plc
- 15.3.11. Owens & Minor, Inc.
- 15.3.12. Smith & Nephew plc
- 15.3.13. Teleflex Incorporated
- 15.3.14. Terumo Corporation
- 15.3.15. TIDI Products, LLC
- 15.3.16. Vygon SAS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
